Breaking News Instant updates and real-time market news.

MYL

Mylan

$31.79

-0.21 (-0.66%)

10:56
08/09/17
08/09
10:56
08/09/17
10:56

Mylan sees high single digit generic price erosion for forseeable future

  • 09

    Aug

  • 03

    Sep

  • 09

    Oct

MYL Mylan
$31.79

-0.21 (-0.66%)

07/18/17
WELS
07/18/17
NO CHANGE
WELS
Market Perform
Novartis report has cautious read-through for Mylan, Teva, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis' (NVS) Sandoz unit is one of the world's largest generic drug makers and he believes the proper read-through from its report is that the U.S. generic market remains challenging and that investors should remain cautious on the generics space. Maris, who said he would not be surprised to see Mylan (MYL) or Teva (TEVA) weaker following Novartis' report, keeps Market Perform ratings on those two names.
08/09/17
RAJA
08/09/17
NO CHANGE
RAJA
Mylan shares more than reflect reset expectations, says Raymond James
Raymond James believes Mylan shares more than adequately reflect the magnitude of reset expectations and is confident, if management can gain confidence in revised 2018 earnings guidance, the stock can quickly bounce back to the mid-$30 range.
08/09/17
WELS
08/09/17
NO CHANGE
Target $30
WELS
Market Perform
Mylan results, outlook confirm cautious stance on generics, says Wells Fargo
Wells Fargo analyst David Maris, who notes that he was cautious on the generic sector heading into Mylan's quarterly report, said the results and outlook communicated by the company have confirmed his caution. Maris, who lowered his 2017 and 2018 estimates for Mylan after the company cut its guidance and said they have elected to defer all major U.S. launches from their FY17 financial view, lowered his price target on the stock to $30 from $34.50. He keeps a Market Perform rating on Mylan.
08/09/17
BMOC
08/09/17
NO CHANGE
BMOC
Outperform
Mylan generic push outs 'disappointing, but not surprising,' says BMO Capital
BMO Capital analyst Gary Nachman said expectations for Mylan have been "very low" even before the company reported on its "challenging" second quarter. While the push out of generic Advair and Copaxone into 2018 is a disappointment, he believes this possibility has been the consensus view among investors. Nachman maintains an Outperform rating on Mylan shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.